Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study

International Journal of Cancer

Volumn 133, Issue 5, 2013, Pages 1187-1196

  Scott, Mark E ^a   Shvetsov, Yurii B ^b   Thompson, Pamela J ^b   Hernandez, Brenda Y ^b   Zhu, Xuemei ^b   Wilkens, Lynne R ^b   Killeen, Jeffrey ^b   Vo, Dien D ^a,c   Moscicki, Anna Barbara ^a   Goodman, Marc T ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c University of California at Berkeley   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

cervix; cytokines; human papillomavirus; interleukins

Indexed keywords

ALPHA2 INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; VIRUS DNA;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UNITED STATES; UTERINE CERVICITIS; UTERINE CERVIX; VIRAL CLEARANCE; VIRUS LOAD;

CERVIX; CYTOKINES; HUMAN PAPILLOMAVIRUS; INTERLEUKINS;

ADOLESCENT; ADULT; CERVIX UTERI; COHORT STUDIES; CYTOKINES; FEMALE; HAWAII; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROPORTIONAL HAZARDS MODELS;

EID: 84879210021     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28119     Document Type: Article

References (50)

1. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
2. Einstein MH, Schiller JT, Viscidi RP, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009; 9: 347-56.
3. Goodman MT, Shvetsov YB, McDuffie K, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res 2008; 68: 8813-24.
4. Kaul R, Hirbod T,. Genital epithelial cells: foot soldiers or fashion leaders? J Leukoc Biol 2010; 88: 427-9.
5. Stanley M,. Immune responses to human papillomavirus. Vaccine 2006; 24 (Suppl): S16-S22.
6. Stanley M,. HPV-immune response to infection and vaccination. Infect Agent Cancer 2010; 5: 19.
7. Daud II, Scott ME, Ma Y, et al. Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int J Cancer 2011; 128: 879-86.
8. Boccardo E, Lepique AP, Villa LL,. The role of inflammation in HPV carcinogenesis. Carcinogenesis 2010; 31: 1905-12.
9. Scott M, Nakagawa M, Moscicki AB,. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001; 8: 209-20.
10. Lieberman JA, Moscicki AB, Sumerel JL, et al. Determination of cytokine protein levels in cervical mucus samples from young women by a multiplex immunoassay method and assessment of correlates. Clin Vaccine Immunol 2008; 15: 49-54.
11. O'Byrne KJ, Dalgleish AG,. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001; 85: 473-83.
12. Balkwill F, Mantovani A,. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
13. Hawes SE, Kiviat NB,. Are genital infections and inflammation cofactors in the pathogenesis of invasive cervical cancer? J Natl Cancer Inst 2002; 94: 1592-3.
14. Bodily J, Laimins LA,. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol 2011; 19: 33-9.
15. Brismar Wendel S, Kaldensjö T, Peterson P, et al. Slumbering mucosal immune response in the cervix of human papillomavirus DNA-positive and -negative women. Int J Oncol 2010; 37: 1565-73.
16. Marks MA, Viscidi RP, Chang K, et al. Differences in the concentration and correlation of cervical immune markers among HPV positive and negative perimenopausal women. Cytokine 2011; 56: 798-803.
17. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998; 132: 277-84.
18. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38: 357-61.
19. Gravitt PE, Peyton CL, Apple RJ, et al. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998; 36: 3020-7.
20. Castle PE,. The evolving definition of carcinogenic human papillomavirus. Infect Agent Cancer 2009; 4: 7.
21. Scott ME, Wilson SS, Cosentino LA, et al. Interlaboratory reproducibility of female genital tract cytokine measurements by Luminex: implications for microbicide safety studies. Cytokine 2011; 56: 430-4.
22. Hwang LY, Scott ME, Ma Y, et al. Higher levels of cervicovaginal inflammatory and regulatory cytokines and chemokines in healthy young women with immature cervical epithelium. J Reprod Immunol 2011; 88: 66-71.
23. Mickey RM, Greenland S,. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989; 129: 125-37.
24. Grambsch PM, Therneau TM,. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515-26.
25. Andersen JM, Al-Khairy D, Ingalls RR,. Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens. Biol Reprod 2006; 74: 824-31.
26. Bhat P, Mattarollo SR, Gosmann C, et al. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunol Rev 2011; 239: 85-98.
27. Reiser J, Hurst J, Voges M, et al. High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol 2011; 85: 11372-80.
28. Takeuchi O, Akira S,. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-20.
29. Coleman N, Birley HD, Renton AM, et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994; 102: 768-74.
30. Davidson B, Goldberg I, Kopolovic J,. Inflammatory response in cervical intraepithelial neoplasia and squamous cell carcinoma of the uterine cervix. Pathol Res Pract 1997; 193: 491-5.
31. Brennan K, Bowie AG,. Activation of host pattern recognition receptors by viruses. Curr Opin Microbiol 2010; 13: 503-7.
32. Kobayashi A, Weinberg V, Darragh T, et al. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol 2008; 1: 412-20.
33. Couper KN, Blount DG, Riley EM,. IL-10: the master regulator of immunity to infection. J Immunol 2008; 180: 5771-7.
34. Karim R, Meyers C, Backendorf C, et al. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One 2011; 6: e17848.
35. Tindle RW,. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002; 2: 59-65.
36. Smith JS, Muñoz N, Herrero R, et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 2002; 185: 324-31.
37. Smith JS, Herrero R, Bosetti C, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002; 94: 1604-13.
38. Feghali CA, Wright TM,. Cytokines in acute and chronic inflammation. Front Biosci 1997; 2: d12-d26.
39. Hudson JD, Shoaibi MA, Maestro R, et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999; 190: 1375-82.
40. O'Byrne KJ, Dalgleish AG, Browning MJ, et al. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 2000; 36: 151-69.
41. Serhan CN, Savill J,. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005; 6: 1191-7.
42. Fadok VA, Bratton DL, Konowal A, et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998; 101: 890-8.
43. Huynh ML, Fadok VA, Henson PM,. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 2002; 109: 41-50.
44. Lucas M, Stuart LM, Savill J, et al. Apoptotic cells and innate immune stimuli combine to regulate macrophage cytokine secretion. J Immunol 2003; 171: 2610-5.
45. Voll RE, Herrmann M, Roth EA, et al. Immunosuppressive effects of apoptotic cells. Nature 1997; 390: 350-1.
46. Hildesheim A, McShane LM, Schiffman M, et al. Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures. J Immunol Methods 1999; 225: 131-43.
47. Franklin RD, Kutteh WH,. Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. J Reprod Immunol 1999; 42: 93-106.
48. Passmore JA, Morroni C, Shapiro S, et al. Papanicolaou smears and cervical inflammatory cytokine responses. J Inflamm (Lond) 2007; 4: 8.
49. Dezzutti CS, Hendrix CW, Marrazzo JM, et al. Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PLoS One 2011; 6: e23136.
50. Bland JM, Altman DG,. A note on the use of the intraclass correlation coefficient in the evaluation of agreement between two methods of measurement. Comput Biol Med 1990; 20: 337-40.